Biosyent Inc logo

RX - Biosyent Inc News Story

C$7.9 0.3  4.0%

Last Trade - 16/04/21

Sector
Healthcare
Size
Small Cap
Market Cap £59.1m
Enterprise Value £45.3m
Revenue £12.9m
Position in Universe 860th / 2713

BioSyent Launches Combogesic®, First-Ever Acetaminophen + Ibuprofen Combination Tablet in Canada Now Available

Wed 16th December, 2020 2:30pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201216:nGNXbPjF75&default-theme=true


MISSISSAUGA, Ontario, Dec. 16, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc.
(“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce
that its subsidiary, BioSyent Pharma Inc., has commenced the first shipments
of Combogesic(®) to Canadian wholesalers. Combogesic(®) is the first
fixed-dose combination of acetaminophen and ibuprofen in a single tablet in
Canada and is indicated for the short-term management of mild to moderate
acute pain and the reduction of fever in adults.

Combining two trusted, familiar, and effective active ingredients,
acetaminophen and ibuprofen, in a new patented formulation, Combogesic(®)
brings together two different modes of action into one effective pain
reliever. Though the two active ingredients have been available in Canada for
decades, Combogesic(®) represents the first Health Canada approved
combination of these proven pain relievers in a single tablet.

“A novel combination of two popular non-prescription analgesics –
ibuprofen and acetaminophen – Combogesic(®) provides clinicians with an
additional therapeutic option for achieving multimodal analgesia for mild to
moderate pain management in adults without compromising the well-established
safety profile of either active constituent,” said Dr. Nardine Nakhla, a
community pharmacist and clinical lecturer at the University of Waterloo
School of Pharmacy.

BioSyent Pharma Inc. in-licensed Combogesic(®) for Canada from AFT
Pharmaceuticals Ltd. who market the product, either directly or through
partners, to 44 other countries under various brand names including
Maxigesic(®). In other markets it comes in different dosage forms and
strengths. The efficacy of Combogesic(®) is based on its clinically proven
unique ratio – one tablet contains 325 mg of acetaminophen and 97.5 mg of
ibuprofen, a 3.3:1 ratio.

Combogesic(®) has a well-established safety and tolerability profile and is
opioid-free. The safety of Combogesic(®) is comparable to similar doses of
either acetaminophen or ibuprofen alone. Examples of acute pain include
headaches, menstrual cramps, sprains, and strains. Acute pain can also occur
from tissue injuries and after surgical operations.

“We are pleased to make Combogesic(®) available to Canadians as a new
option for the management of acute pain and reduction of fever,” said René
Goehrum, President and CEO of BioSyent. “Canadians consume over 2.7 billion
doses of analgesics annually to treat acute pain or fever and our research
tells us that a portion of this market is not satisfied. We are excited to
achieve this milestone of bringing Combogesic(®) to the market and to have it
contribute to the long-term growth and diversification of our Canadian
pharmaceutical business.”

Combogesic(®) is available without a prescription by simply asking at the
pharmacy counter or by ordering on-line.

You can find more information about Combogesic(®) at www.Combogesic.ca

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent
is a profitable growth-oriented specialty pharmaceutical company focused on
in-licensing or acquiring innovative pharmaceutical and other healthcare
products that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients. BioSyent
supports the healthcare professionals that treat these patients by marketing
its products through its community, specialty/hospital and international
business units.

As of the time of this press release, the Company has 12,805,200 common shares
outstanding.

For a direct market quote for the TSX Venture Exchange and other Company
financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f0a4a060-1c11-4af4-8e1d-8f245ff50f9d



(https://www.globenewswire.com/NewsRoom/AttachmentNg/3dded277-7953-4418-be63-7d7a3067811d)
Combogesic(R) Packagw 
(https://www.globenewswire.com/NewsRoom/AttachmentNg/f0a4a060-1c11-4af4-8e1d-8f245ff50f9d/en)
Combogesic(R) Package


GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.